Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis

Hepatology

Volumn 23, Issue 1, 1996, Pages 164-176

  Arroyo, Vicente ^a   Ginès, Pere ^a   Gerbes, Alexander L ^b   Dudley, Francis J ^c   Gentilini, Paolo ^d   Laffi, Giacomo ^d   Reynolds, Telfer B ^e   Ring Larsen, Helmer ^f   Schölmerich, Jürgen ^g  

^a HOSPITAL CLÍNIC   (Spain)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASCITES; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; HEPATORENAL SYNDROME; HISTORY; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LIVER CIRRHOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SODIUM RESTRICTION; VASOCONSTRICTION;

EID: 0030052899     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v23.ajhep0230164     Document Type: Article

References (24)

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
2. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993;73:375-411.
3. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
4. Bomzon A, Blendis LM, The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. HEPATOLOGY 1994;20:1343-1350.
5. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide. Lancet 1991;337:776-778.
6. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-1778.
7. Ginès P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987;92:234-241.
8. Ferral H, Bjarnason H, Wegryn SA, Rengel GJ, Nazarian GK, Rank JM, Tadavarthy SM, et al. Refractory ascites: early experience in the treatment with transjugular intrahepatic portosystemic shunt. Radiology 1993;189:795-801.
9. Clària J, Jiménez W, Arroyo V, Guarner F, López C, LaVilla G, Asbert M, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 1989;97:1294-1299.
10. Tsuboi Y, Ishikawa SE, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994;46:237-244.
11. Bosch-Marcé M, Jiménez W, Angeli P, Leivas A, Ciaria J, Graziotto A, Arroyo V, et al. Aquaretic efficacy of the kappa opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995;109:217-223.
12. Llovet JM, Bartoli R, Planas R, Cabré E, Jiménez W, Urban A, Ojanguren J, et al. Bacterial translocation in cirrhotic rats. Its role in the development of SEP. Gut 1994;35:1648-1652.
13. Byl B, Roucloux I, Crusiaux A, Dupont E, Devière J. Tumor necrosis factor alpha and interleukin-6 plasma levels in infected cirrhotic patients. Gastroenterology 1993;104:1492-1497.
14. Arroyo V, Navasa M, Rimola A. Spontaneous bacterial peritonitis in cirrhosis. Treatment and prophylaxis. Infection 1994;22 (suppl 3):167S-175S.
15. Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. HEPATOLOGY 1990;12:716-724.
16. Soriano G, Guarner C, Teixido M, Such J, Barrios J, Enriquez J, Vilardell J. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-481.
17. Earley LE. Presentation of diagnostic criteria of the hepatorenal syndrome. In: Bartoli E, Chiandussi L, eds. Hepatorenal Syndrome. Padova: Piccin Medical Books, 1979:495-504.
18. Arroyo V, Epstein M, Gallus G, Gentilini P, Ring-Larsen H, Salerno F. Refractory ascites in cirrhosis. Mechanism and management. Gastroenterology Int 1989;2:195-207.
19. Arroyo V, Ginès A, Saló J. A European survey on the treatment of ascites in cirrhosis. J Hepatol 1994;21:667-672.
20. Czaja AJ. Chronic active hepatitis: the challenge for a new nomenclature. Ann Intern Med 1993;119:510-517.
21. Bernardi M, Di Marco C, Trevisani F, Fornalé L, Andreone P, Cursaro C, Baraldini M, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993;105:188-193.
22. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis 1994;14:23-34.
23. Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983;84:961-968.
24. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis 1994;14:35-43.